COVID-19: Information for hospitals and health systems
More than half of US hospitals and health systems trust Quest Diagnostics to deliver accurate and timely test results every day. During the COVID-19 pandemic, you can continue to rely on our fast action and clear insights in the face of uncertainty.
Just as we have during other health emergencies, the entire Quest team is rising above the challenge at hand. We’re here to empower your hospital and the communities you serve.
Quest helps strengthen your connection to the patients and healthcare workers who put their trust in you.
This page is updated frequently as new information becomes available and we continue increasing testing capacity to meet your needs.
Quest Diagnostics is receiving COVID-19 specimens and performing testing nationwide.
The following co-testing options can help differentially detect or evaluate the pathogen(s) responsible for a patient’s respiratory infection. These co-testing options include many clinical advantages including, but not limited to, collecting a single specimen, potentially minimizing patient discomfort, and expediting time to diagnosis.
These tests include:
- SARS-CoV-2 RNA (COVID-19) and Influenza A and B, Qualitative NAAT (test code 31688)
- SARS-CoV-2 RNA (COVID-19) and Respiratory Pathogen Panel, Qualitative NAAT (test code 31687)
- SARS-CoV-2 RNA (COVID-19) and Respiratory Viral Panel, Qualitative NAAT (test code 31686)
The following testing options can help identify recent or prior infection with SARS-CoV-2 (which may be resolved or is still resolving):
Quest Diagnostics patient service centers are not accepting patients with suspected or confirmed COVID-19 and are not collecting respiratory specimens for COVID-19 molecular testing.
Blood specimens for SARS-CoV-2 antibody testing can be collected by a hospital or health system or in any healthcare setting where a licensed phlebotomist can draw blood. Quest will be collecting serology specimens at patient service centers (PSCs) by appointment across the country.
The personnel at our PSCs are trained in collecting a range of specimens, including blood and urine, for various medical health conditions, but not respiratory specimens for COVID-19 or other respiratory illnesses such as influenza.
Quest recommends individuals who suspect they have COVID-19 contact their healthcare provider directly about COVID-19 testing. Quest laboratories are accepting and performing testing on COVID-19 specimens submitted by healthcare providers across the United States.
Important information about SARS-CoV-2 (COVID-19) testing
Note: The antibody tests are intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Results are for the detection of SARS-CoV-2 antibodies. IgG and IgM antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Individuals may have detectable virus present for several weeks following seroconversion. Negative results do not preclude acute SARS-CoV-2 infection. If acute infection is suspected, molecular testing for SARS-CoV-2 is necessary. The antibody tests should not be used to diagnose acute SARS-CoV-2 infection. False positive results for the antibody tests may occur due to cross-reactivity from pre-existing antibodies or other possible causes.
The antibody tests and the molecular tests have not been FDA cleared or approved;
All tests have been authorized by FDA under EUAs for use by authorized laboratories;
The antibody tests have been authorized only for the detection of IgG and IgM antibodies against SARS-CoV-2, not for any other viruses or pathogens;
The molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and,
All tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner